What Is iRadimed Corporation (IRMD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, iRadimed Corporation's intrinsic value is estimated at $41.24. Trading at its current price of $97.69, the valuation engine raises significant caution: 12 of 13 models flag downside risk, projecting an average implied return of -57.8%. The most optimistic model, Markov DDM, places fair value at $116.95 (+19.7%), while Dynamic NAV — the most conservative — estimates $6.59 (-93.3%). This +113.0% gap reflects genuine analytical uncertainty about iRadimed Corporation's intrinsic worth. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About IRMD?
13 of 13 models are currently active for IRMD. Of these, 1 model suggests upside while 12 models suggest overvaluation. The Bayesian DCF estimates IRMD's intrinsic value at $24.87, implying -74.5% downside from the current price. See which stocks rank higher →
How Does IRMD Rank in Surgical & Medical Instruments & Apparatus?
Among 111 Surgical & Medical Instruments & Apparatus stocks, IRMD ranks #2 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places IRMD in the top tier.
See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →
iRadimed Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is IRMD a Value Trap?
CirclFi's Value Trap algorithm assigns IRMD a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for iRadimed Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, iRadimed Corporation earns a quality score of 10.0/10. This exceptional rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +113.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IRMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IRMD's 13 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad